Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the ...

Amarin's blockbuster hopes for fish oil derivative Vascepa came to a crashing halt in March after a district judge struck down its key patents, just months after a major new FDA approval. Amarin put ...

DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results ...

Amarin Corporation and Sarissa Capital Management, the company’s largest shareholder, have engaged in a public war of words this month over a recent board refreshment process. Amarin, a New ...

Amarin Corp. announced June 6 it tapped 20-year finance veteran Tom Reilly as chief financial officer, effective June 20. He will succeed Michael Kalb, who came on board in June 2016 and will leave ...

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa Capital believes that today’s ...

Amarin estimates preliminary Q4 revenue between $72 million and $74 million and between $304 million and $306 million for 2023. The company also announces a conditional share repurchase program of up ...

Amarin appointed a new president and CEO Tuesday in the midst of an organizational restructuring aiming to stem its plummeting revenue. Patrick Holt will take over to helm the company, replacing Aaron ...